Tema Etfs LLC Invests $1.87 Million in BeOne Medicines Ltd. – Sponsored ADR $ONC

Tema Etfs LLC acquired a new stake in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 7,707 shares of the company’s stock, valued at approximately $1,866,000.

Other large investors have also bought and sold shares of the company. Legal & General Group Plc acquired a new stake in shares of BeOne Medicines during the second quarter worth $13,857,000. Slow Capital Inc. acquired a new position in BeOne Medicines in the 2nd quarter worth $4,377,000. Public Employees Retirement System of Ohio acquired a new position in BeOne Medicines in the 2nd quarter worth $3,491,000. Fox Run Management L.L.C. bought a new position in BeOne Medicines during the 2nd quarter worth about $496,000. Finally, Artisan Partners Limited Partnership acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $65,396,000. 48.55% of the stock is owned by institutional investors.

BeOne Medicines Stock Performance

NASDAQ ONC opened at $331.40 on Friday. The stock has a market cap of $39.28 billion, a PE ratio of 649.80 and a beta of 0.45. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. The firm has a 50-day moving average of $332.91 and a 200-day moving average of $301.64. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $170.99 and a 52-week high of $385.22.

Analysts Set New Price Targets

Several research firms have recently weighed in on ONC. Citigroup upped their price objective on BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Citizens Jmp upped their price target on BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Truist Financial set a $400.00 target price on shares of BeOne Medicines in a report on Monday, November 24th. Barclays began coverage on shares of BeOne Medicines in a research note on Thursday, September 18th. They issued an “overweight” rating and a $385.00 price target on the stock. Finally, Morgan Stanley boosted their price target on shares of BeOne Medicines from $350.00 to $383.00 and gave the stock an “overweight” rating in a research report on Monday, October 20th. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $365.79.

Insider Activity

In other news, SVP Chan Henry Lee sold 996 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $349.17, for a total transaction of $347,773.32. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Lai Wang sold 5,000 shares of the business’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $350.06, for a total value of $1,750,300.00. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 81,094 shares of company stock valued at $27,929,161. Company insiders own 6.62% of the company’s stock.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.